Cynata completes patient enrollment for Phase 2 aGvHD clinical trial
Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease
Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease
The ChemiSphere app exemplifies how M-Trust technology transforms workflows into seamless digital experiences
Bertozzi currently serves as the Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor at Stanford University, and Investigator of the Howard Hughes Medical Institute
India plays a critical role in Bristol Myers Squibb’s global strategy
The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
The company operates a chain of mid-sized multi-speciality hospitals
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants
Subscribe To Our Newsletter & Stay Updated